top of page

News of Note - February 23, 2023


Thursday, February 23, 2023


My strategy remains purely healthcare (still in defense mode – call it neutral allocation) though my focus has been tugged at by other entities as it has been a bit sleepy in the sector to kick off the year..

Sanofi, Novartis, and UCB have made it into the portfolio (and I really *want* to own a lot of UCB for some reason) as I look to ‘normalize’ things over time..

Along these lines the biotech allocation has remained the same overall though it is now more concentrated, into a mere seven positions..


Br. -john

p.s. Bill Gates into 'green bottles' X) 👇





Volvo leads the booming market for electric trucks

  • Volvo Trucks have now sold more than 4,300 electric trucks globally in more than 38 countries.

  • In Europe, Volvo Trucks is the market leader with a 32% share of the market for heavy electric trucks, and in North America, nearly half of all heavy electric trucks registered in 2022 were Volvo trucks.

AB Volvo (publ), together with its subsidiaries, manufactures and sells trucks, buses, construction equipment, and marine and industrial engines in Europe, North America, South America, Asia, Africa, and Oceania. -CapIQ

GSK LN | GSK, PFE, 4507 JT

GSK, Pfizer, Shionogi

ViiV Healthcare announces positive data demonstrating long-acting injectable Cabenuva (cabotegravir, rilpivirine) is as effective as daily oral Biktarvy (BIC/FTC/TAF) for the treatment of HIV-1

  • 12-month findings from the SOLAR study showed that the every-two-month regimen of CAB+RPV LA demonstrated non-inferior efficacy compared to continuation of daily oral BIC/FTC/TAF

  • 90% of participants who switched from BIC/FTC/TAF to CAB+RPV LA preferred the complete long-acting regimen to daily pills

  • cc: GILD

ViiV Healthcare Limited delivers care and treatment for the people living with HIV/AIDS. -CapIQ



Enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate

  • CMG901 expands AstraZeneca’s commitment in gastric cancer

  • upfront payment of $63m

  • additional development and sales-related milestone payments of up to $1.1bn

  • as well as tiered royalties up to low double digits

  • KYM Biosciences is a joint venture established by affiliates of Keymed Biosciences and Lepu Biopharma

  • cc: 2162 HK, 2291 HK

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. -CapIQ



Receives NLAW Order from Finland

Saab AB (publ) provides products, services, and solutions for the military defense, aerospace, and civil security markets worldwide. -CapIQ



This is the other half of the Roche story - the side which deserves more attention in my honest opinion.. If Roche does great in the 2020's it is likely this division (diagnostics) played an outsized role..

Launches two new antibodies to identify key clinical mutations in patients with brain cancer

  • Recent advances in cancer genomics have deepened the medical community’s understanding of the molecular alterations in brain tumours, more precisely subclassifying patients into specific diagnoses.

  • Understanding a patient's brain tumour mutation status in the IDH1 and ATRX genes enables more informed clinical decisions and may improve patient outcomes.

  • The IDH1 R132H and ATRX antibodies are the latest additions to Roche’s neuropathology portfolio, which contains 29 biomarkers.

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. -CapIQ


Merck & Moderna

Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Melanoma Following Complete Resection

  • Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. -CapIQ

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. -CapIQ



Release/ Report



Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. -CapIQ



To Build New Transmission Tower Production Plant in Alabama

Nucor Corporation manufactures and sells steel and steel products. -CapIQ



Announces Update on Preliminary Safety and Efficacy Data from FORTIS Study of Investigational AT845 in Adults with Late-Onset Pompe Disease

  • Data presented at the 19th Annual WORLDSymposium™ 2023

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals in the Japan, United States, and internationally.-CapIQ


Prometheus Biosciences

Announces Two Oral Presentations on PRA023 at the 18th Congress of European Crohn’s and Colitis Organisation (ECCO)

  • Digital Oral Presentation on APOLLO-CD Phase 2a primary and secondary results to be presented on March 3rd

  • Oral Presentation on ARTEMIS-UC Phase 2 primary and secondary endpoint data from Cohort 1 to be presented on March 4th

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). -CapIQ




Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A

  • cc: BMRN

Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B

  • cc: QURE & CSL AU

Hemophilia A Gene Therapy — Some Answers, More Questions

Rucaparib or Physician’s Choice in Metastatic Prostate Cancer



GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill

  • cc: GSK LN | GSK, PFE, & 4507 JT x GILD


Biotech rents hold firm as demand for lab space slumps

  • Life science vacancy levels across major biotech hubs increased throughout last year, from 4.8% in the first quarter of 2022 to 7.5% during the fourth quarter, according to data from JLL.

  • cc: ARE

Charles River suspends shipments of monkeys used in research amid federal probe

  • Charles River is not the only company to hit the pause button as a result of the federal investigation.

  • cc: CRL


Bill Gates Buys Stake in Heineken for $902 Million

  • The Microsoft founder and philanthropist last week picked up 3.8% of Heineken Holding, according to a filing by the Dutch regulator AFM.

  • He bought 6.65 million shares in Heineken Holding, in his individual capacity, and another 4.18 million shares through the Bill & Melinda Gates Foundation Trust.

  • Heineken Holding controls 50% of Heineken NV, maker of the namesake beer as well as Amstel, Moretti, and Sol among others.

  • cc: HEIA NA, HEIO NA

Watchfinder Cuts Prices 15% as Rolex and Patek Philippe Values Slide

  • Average price of £7,000 continues for watches put up for sale

  • Rolex remains the most popular brand in pre-owned market


All quiet on the deal front... or perhaps it’s just February

US deal watchdog's bark could be worse than its bite

  • Chills in the biopharma M&A market are frequently blamed on the FTC. But is the agency really stopping deals from happening?

Financial Times

These two stories jumping off the screen, whatever the macro narrative is - companies are most definitely taking the opportunity to clean house..

Rolls-Royce launches sweeping review in turnround bid

  • New chief Tufan Erginbilgic vows UK’s flagship engineering group is capable of much more

  • cc: RR. LN

Anglo American takes $1.7bn writedown on Yorkshire fertiliser mine

  • Mining group estimates it would spend $1bn a year to bring Woodsmith mine into production by 2027

  • cc: AAL LN


Toyota accepts union demands for biggest wage hike in two decades

  • Deal sets a benchmark for Japan's auto industry - Toyota exec

  • Honda agrees with union to raise pay by 5%

  • Japan battling highest inflation in 40 years

  • cc: 7203 JT | TM

bottom of page